帕金森病痴呆和路易体痴呆在 11 C-PIB PET/CT脑显像及脑脊液检测中的差异分析

Abstract

Objective To analyze differences in the imaging and biomarkers of patients with Parkinson disease dementia(PDD) and those with dementia with Lewy bodies(DLB) by 11C-pittsburgh compound B(PIB) PET/CT imaging and testing of different proteins in the cerebrospinal fluid. Methods A total of 10 PDD patients(PDD group) including six males and four females, aged 57-79 years(mean, 69.9±6.57 years) and 11 DLB patients(DLB group) including six males and five females, aged 62–80 years(mean, 71.09±5.65 years), clinically diagnosed from June 2011 to February 2018 were recruited to this study. Brain scans were performed using 11C-PIB PET/CT to measure the mean standardized uptake value(SUVmean) ratios of the frontal lobe, parietal lobe, temporal lobe, occipital lobe, thalamus, and striatum to cerebellum. The concentrations of tau, amyloid β-protein42(Aβ42), and cluster proteins in the cerebrospinal fluid were determined by double-antibody sandwich enzymelinked immunosorbent assay. T test was used to compare the SUVmean ratio of different brain regions to that of the cerebellum, as well as the protein levels of cerebrospinal fluid between the two groups. Results The ratio of 11C-PIB SUVmean in each brain region relative to that in the cerebellum was higher in DLB patients than in PDD patients, and differences between the two groups in the frontal lobe(DLB group: 1.52±0.28, PDD group: 1.21±0.25) and striatum(DLB group: 1.46±0.26, PDD group: 1.20±0.21) were statistically significant(t=-2.596, –2.504, P=0.018, 0.022). Tau levels in the DLB group[(582.7±304.50) ng/L] were higher than those in the PDD group[(344.10±133.37) ng/L]; by contrast, levels of Aβ42 and cluster proteins[(491.73±136.54) ng/L, (5219.45±1999.10) μg/L] in the DLB group were lower than those in the PDD group[(644.70±311.77) ng/L, (8358.30±3014.51) μg/L]. Tau and cluster proteins showed statistically significant differences between the two groups(t=–2.283, 2.838, P=0.034, 0.011). Conclusion PDD and DLB show many obvious differences during 11C-PIB PET/CT brain imaging and cerebrospinal fluid testing, and these differences can provide a basis for clinical differential diagnosis. Key words: Positron emission tomography computed tomography; Parkinson disease dementia; Dementia with Lewy bodies; Cerebrospinal fluid; Pittsburgh compound B